Rentokil Rises After Goldman Sachs Upgrade

Introduction: The Tuesday When the Rats Retreated

Tuesday, London Stock Exchange. Shares of Rentokil Initial PLC, a company known across Britain — from housewives to restaurant owners — unexpectedly came back to life. While the FTSE 100 index remained almost unchanged, Rentokil rose by 2.1%, climbing to 453.5 pence per share. The reason behind the move was an upgrade from Goldman Sachs.

Goldman Sachs, one of the world’s leading investment banks, upgraded Rentokil to “Buy” from “Neutral” and raised its 12-month price target to 590 pence from 515 pence. This implies around 33% upside potential compared with the previous closing price. For investors, this is a signal that the pest control company, which has gone through a difficult period after acquiring Terminix, is finally beginning to recover.

So what has changed? The main factor is improving operating performance in North America, Rentokil’s largest market. After several years of instability related to the integration of Terminix, the company has begun to steadily restore organic growth. Goldman Sachs expects the business to return to mid-single-digit organic growth by 2027, narrowing the performance gap with industry rival Rollins.

The broker also noted that the suspension of the main Terminix integration work reduced operational disruptions, allowing management to focus on improving execution while gradually expanding margins. The group’s EBITA margin is expected to rise to 17.1% in 2027.

Let’s take a closer look at what is really happening with Rentokil, why Goldman Sachs upgraded the stock, and what this means for investors.

What Is Rentokil Initial and Why Does It Matter?

Pest Control and More

Rentokil Initial is not just a company that eliminates rats and cockroaches. It is a global giant in the hygiene and sanitation services sector, operating in dozens of countries around the world. Its services include pest control, workplace hygiene, plant care, and other professional services.

The company was founded in 1924 and has since grown into one of the leaders in its sector. Its clients include private households as well as large corporations, restaurants, hotels, and government institutions.

Rentokil is known for its green branding and recognizable logo. In the United Kingdom, its services have become almost synonymous with pest control — when someone has mice or rats, they call Rentokil.

The Terminix Acquisition: A Big Step With Consequences

In 2022, Rentokil made a major acquisition by purchasing the American company Terminix, which also specializes in pest control. The deal was worth around $6.7 billion.

The acquisition was a strategically sound move that allowed Rentokil to strengthen its position in the North American market. However, integrating two large companies proved to be a difficult task. Rentokil’s organic growth slowed, and the company’s shares declined.

Investors were concerned that Rentokil would not be able to integrate Terminix effectively and that the deal would fail to meet expectations. This created pressure on the stock, which traded significantly below its historical highs.

Goldman Sachs Upgrade: What Has Changed?

Improving Operating Performance

Goldman Sachs upgraded Rentokil to “Buy” amid improving operating performance in North America. The broker noted that organic growth in the region has improved since the third quarter of 2025.

This improvement was made possible by continued investment in branch network expansion, local sales, customer retention, and marketing. Rentokil is actively working to restore customer confidence and increase its market share.

Goldman Sachs expects Rentokil’s North American business to return to mid-single-digit organic growth by 2027. This means the company should be able to narrow the performance gap with industry rival Rollins.

Fewer Operational Disruptions

Goldman Sachs also noted that the suspension of the main Terminix integration work reduced operational disruptions. This allowed Rentokil’s management to focus on improving execution and gradually expanding margins.

The integration of two large companies always involves risks. However, Rentokil now appears to be starting to manage those risks more effectively. The management team has been able to improve processes and return its focus to operational efficiency.

Profit and Margin Forecasts

Goldman Sachs expects the group’s EBITA margin to rise to 17.1% in 2027, supported by stronger revenue growth and continued cost savings.

The broker also slightly raised its profit forecasts for 2027 and 2028. This confirms its confidence that Rentokil is on the right path toward recovery.

Why Rentokil Shares Rose

Market Reaction to the Upgrade

Rentokil shares rose by 2.1% to 453.5 pence after the upgrade from Goldman Sachs. This was a notable move, especially against the backdrop of an almost unchanged FTSE 100.

The market reacted positively to the news of the rating upgrade and higher price target. Investors interpreted it as confirmation that Rentokil is on the road to recovery.

The new price target of 590 pence implies around 33% upside potential compared with the previous closing price. This creates an attractive opportunity for investors who believe in the company’s long-term potential.

An Attractive Entry Point

Goldman Sachs indicated that the recent correction in Rentokil shares has created an attractive entry point. The company’s shares are trading significantly below their historical highs, while improving industry fundamentals and stronger operating results make them attractive for purchase.

Investors who are willing to wait for Rentokil’s recovery could generate significant returns in the coming years.

Lower Debt Burden

Another positive factor is the continued reduction of the debt burden. Rentokil is actively paying down the debt taken on to acquire Terminix, creating room for future targeted acquisitions in the fragmented pest control market.

The pest control market remains fragmented, and Rentokil has an opportunity to strengthen its position through additional acquisitions. Lower debt gives the company the financial flexibility to pursue this strategy.

Rentokil’s Prospects

Recovery in Organic Growth

Rentokil’s main task is to restore organic growth. Goldman Sachs expects this to happen by 2027, when the business is projected to return to mid-single-digit organic growth.

This will require continued investment in network expansion, marketing, and customer retention. But if Rentokil can execute this plan, its shares may rise significantly.

Competition With Rollins

Rollins is Rentokil’s main competitor in the North American market. Goldman Sachs expects Rentokil to narrow the performance gap with Rollins, which could support a re-rating of the stock.

Rollins has traditionally delivered higher organic growth, but Rentokil has the advantage of scale and global presence. If Rentokil can improve its operating performance, it may become more competitive.

The Role of Acquisitions

Rentokil may also use acquisitions to strengthen its position. The pest control market remains fragmented, and Rentokil has the opportunity to acquire smaller players to expand its network and increase market share.

The reduction in debt gives the company financial flexibility to implement this strategy.

Conclusion: Rentokil Is on the Road to Recovery

Rentokil Initial PLC rose by 2.1% after Goldman Sachs upgraded the stock. The broker raised its rating to “Buy” from “Neutral” and increased its 12-month price target to 590 pence from 515 pence.

Goldman Sachs highlighted the improvement in Rentokil’s operating performance in North America, the company’s largest market. Organic growth in the region has improved since the third quarter of 2025 thanks to investments in branch network expansion, local sales, customer retention, and marketing.

The broker expects Rentokil’s North American business to return to mid-single-digit organic growth by 2027, narrowing the performance gap with industry rival Rollins.

The suspension of the main Terminix integration work reduced operational disruptions and allowed management to focus on improving execution. The group’s EBITA margin is expected to rise to 17.1% in 2027.

Goldman Sachs also noted that the recent correction in Rentokil shares has created an attractive entry point, given improving industry fundamentals and stronger operating results at the company. Lower debt supports future targeted acquisitions in the fragmented pest control market.

Rentokil is on the road to recovery. If the company can execute its plans, its shares may rise significantly. Investors who believe in Rentokil’s long-term potential could generate profits in the coming years.